Michael Makris/LinkedIn
Nov 19, 2025, 02:49
Michael Makris: Novo Nordisk has Decided to Discontinue Their Haemophilia A Gene Editing Program
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
“Novo Nordisk has decided to discontinue their haemophilia A gene editing program.
Novo Nordisk have had concizumab approved recently, and I expect their bispecific Mim8 to be approved soon. I expect this had a major impact on the decision to discontinue the gene editing program.”
Stay updated with Hemostasis Today.
-
Sep 16, 2026, 16:06Katrina Louise Manalaysay: In Your 20s, You Might be Given the Opportunity to Donate Blood for the First Time
-
Sep 16, 2026, 15:45Matthew Hazell: A Brilliant Explanation of Phenotype vs Genotype Using a LEGO House
-
Sep 16, 2026, 15:23Ahmad Al-Ramahi: Presenting the Military Pharmacists Blood Training Course at the FIP World Congress
-
Sep 16, 2026, 15:21HIT Reimagined: Can 12-Lipoxygenase Inhibition Stop Immune Thrombosis?
-
Sep 16, 2026, 14:42Ruchi Punamia: Beyond the Blood Bank and The Clinical Impact of Apheresis
-
Sep 16, 2026, 14:06Kalyan Roy: Celebrating Apheresis, Advancing Care, Saving Lives
-
Sep 16, 2026, 13:38Andrew Zapfel: Advancing Sickle Cell Disease Care and Research
-
Sep 16, 2026, 13:30Thirunavukkarasu Angappan: Why Plasma-Derived Factor VIII Still Matters for Inhibitor Patients
-
Sep 16, 2026, 13:22Matthew Hazell: New BSH Guidance for Fetal, Neonatal and Paediatric Transfusion